SinoMab BioScience (FRA:4VF) PS Ratio: (As of Sep. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4VF SinoMab BioScience Ltd FRA:4VF
19 GF Score
Price €0.12
! 2 Warning Signs
View Full Analysis

What is SinoMab BioScience PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, SinoMab BioScience's share price is €0.117. SinoMab BioScience's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Hence, SinoMab BioScience's PS Ratio for today is .

The historical rank and industry rank for SinoMab BioScience's PS Ratio or its related term are showing as below:

During the past 9 years, SinoMab BioScience's highest PS Ratio was 1930.00. The lowest was 34.06. And the median was 590.00.

FRA:4VF's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.545
* Ranked among companies with meaningful PS Ratio only.

SinoMab BioScience's Revenue per Sharefor the six months ended in Dec. 2025 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.

During the past 12 months, the average Revenue per Share Growth Rate of SinoMab BioScience was -100.00% per year.

During the past 9 years, SinoMab BioScience's highest 3-Year average Revenue per Share Growth Rate was -60.30% per year. The lowest was -60.30% per year. And the median was -60.30% per year.

Back to Basics: PS Ratio


SinoMab BioScience  (FRA:4VF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


SinoMab BioScience PS Ratio Related Terms


SinoMab BioScience PS Ratio Historical Data

* Premium members only.

The historical data trend for SinoMab BioScience's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SinoMab BioScience PS Ratio Chart

SinoMab BioScience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only 89.38 0.00 0.00 545.00 0.00

SinoMab BioScience Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 545.00 0.00 0.00 0.00

FRA:4VF vs VRTX, REGN, MRNA: PS Ratio Comparison

For the Biotechnology subindustry, SinoMab BioScience's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's PS Ratio distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's PS Ratio falls into.


FRA:4VF
19GF Score
SinoMab BioScience Ltd FRA:4VF
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SinoMab BioScience PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

SinoMab BioScience's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.117/0
=

SinoMab BioScience's Share Price of today is €0.117.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


SinoMab BioScience Business Description

Other Exchanges 03681:Hong Kong
Address No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score

Get the complete analysis for FRA:4VF

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price